Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation

Cytometry Part A

Volumn 81 A, Issue 10, 2012, Pages 865-873

  Ingargiola, M ^a   Dittfeld, C ^a   Runge, R ^a,b   Zenker, M ^a,c   Heldt, J M ^a,c   Steinbach, J ^a,c   Cordes, N ^a,b   Baumann, M ^a,b   Kotzerke, J ^a,b   Kunz Schughart, L A ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

2 D cell culture; Antibody binding; Cell based assay; Chelators; Competitive binding; EGFR ErbB1; Flow cytometry; Radionuclide

Indexed keywords

ANTIBODY CONJUGATE; CETUXIMAB; CHELATING AGENT; DRUG CARRIER; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOTHIOCYANIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; N (2 AMINO 3 (4 ISOTHIOCYANATOPHENYL)PROPYL)CYCLOHEXANE 1,2 DIAMINE N,N',N',N'',N'' PENTAACETIC ACID; N-(2-AMINO-3-(4-ISOTHIOCYANATOPHENYL)PROPYL)CYCLOHEXANE-1,2-DIAMINE-N,N',N',N'',N''-PENTAACETIC ACID; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ARTICLE; BINDING COMPETITION; CHEMISTRY; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; IMMUNOASSAY; IMMUNOLOGY; METABOLISM; METHODOLOGY; PROTEIN BINDING; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; BINDING, COMPETITIVE; CELL LINE, TUMOR; CHELATING AGENTS; DRUG CARRIERS; FLOW CYTOMETRY; FLUORESCENCE; HUMANS; IMMUNOASSAY; IMMUNOCONJUGATES; ISOTHIOCYANATES; PENTETIC ACID; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; YTTRIUM RADIOISOTOPES;

EID: 84866611622     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22110     Document Type: Article

References (44)

1. Huston JS, George AJ. Engineered antibodies take center stage. Hum Antibodies 2001; 10: 127-142.
2. Nieri P, Donadio E, Rossi S, Adinolfi B, Podesta A. Antibodies for therapeutic uses and the evolution of biotechniques. Curr Med Chem 2009; 16: 753-779.
3. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
4. Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol 2008; 6: 742-750.
5. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584.
6. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999; 5: 2884-2890.
7. Milas L, Fan Z, Andratschke NH, Ang KK. Epidermal growth factor receptor and tumor response to radiation: In vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004; 58: 966-971.
8. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK, Chen PB. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997; 15: 1191-1197.
9. Loeffler-Ragg J, Schwentner I, Sprinzl GM, Zwierzina H. EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs 2008; 17: 1517-1531.
10. Sartor CI. Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors. Nat Clin Pract Oncol 2004; 1: 80-87.
11. Zips D, Krause M, Yaromina A, Dörfler A, Eicheler W, Schutze C, Gurtner K, Baumann M. Epidermal growth factor receptor inhibitors for radiotherapy: Biological rationale and preclinical results. J Pharm Pharmacol 2008; 60: 1019-1028.
12. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940.
13. Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, Spencer SA, Buchsbaum DJ, Saleh MN, Stackhouse MA, LoBuglio AF, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000; 18: 47-53.
14. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49: 427-433.
15. Krause M, Schutze C, Petersen C, Pimentel N, Hessel F, Harstrick A, Baumann M. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: A study on C225 in FaDu hSCC. Radiother Oncol 2005; 74: 109-115.
16. Feng FY, Lopez CA, Normolle DP, Varambally S, Li X, Chun PY, Davis MA, Lawrence TS, Nyati MK. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res 2007; 13: 2512-2518.
17. Gurtner K, Deuse Y, Butof R, Schaal K, Eicheler W, Oertel R, Grenman R, Thames H, Yaromina A, Baumann M, et al. Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol 2011; 99: 323-330.
18. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 3234-3243.
19. Frampton JE. Cetuximab: A review of its use in squamous cell carcinoma of the head and neck. Drugs 2010; 70: 1987-2010.
20. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-Year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
21. Dillman RO. Monoclonal antibodies in the treatment of malignancy: Basic concepts and recent developments. Cancer Invest 2001; 19: 833-841.
22. Mathew M, Verma RS. Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009; 100: 1359-1365.
23. Rades D, Wolff C, Nadrowitz R, Breunig C, Schild SE, Baehre M, Meller B. Radioactive EGFR antibody cetuximab in multimodal cancer treatment: Stability and synergistic effects with radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75: 1226-1231.
24. Zenker M, Bergmann R, Walther M, Heldt JM, Pietzsch J, Pietzsch HJ, Steinbach J. Preparation and characterization of (90)Y- and (177)Lu-labeled cetuximab for therapeutic applications in vitro and in vivo. Nucl Med Biol 2010; 37: 723-723.
25. Eicheler W, Zips D, Dörfler A, Grenman R, Baumann M. Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J Histochem Cytochem 2002; 50: 197-204.
26. Dittfeld C, Dietrich A, Peickert S, Hering S, Baumann M, Grade M, Ried T, Kunz-Schughart LA. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116. Radiother Oncol 2010; 94: 375-383.
27. Eke I, Leonhardt F, Storch K, Hehlgans S, Cordes N. The small molecule inhibitor QLT0267 radiosensitizes squamous cell carcinoma cells of the head and neck. PLoS One 2009; 4: e6434.
28. Maecker HT, Trotter J. Selecting reagents for multicolor flow cytometry with BD LSRII and BD FACSCanto systems. [Application Notes]. Nat Methods 2008;5:an6-an7.
29. Maecker HT, Frey T, Nomura LE, Trotter J. Selecting fluorochrome conjugates for maximum sensitivity. Cytometry Part A 2004; 62A: 169-173.
30. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010; 21: 2153-2163.
31. Gangopadhyay A, Petrick AT, Thomas P. Modification of antibody isoelectric point affects biodistribution of 111-indium-labeled antibody. Nucl Med Biol 1996; 23: 257-261.
32. Eiblmaier M, Meyer LA, Watson MA, Fracassol PM, Pike LJ, Andersonl CJ. Correlating EGFR expression with receptor-binding properties and internalization of Cu-64-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 2008; 49: 1472-1479.
33. Lee HJ, Pardridge WM. Monoclonal antibody radiopharmaceuticals: Cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging. Bioconjug Chem 2003; 14: 546-553.
34. Hantash J, Smidt M, Bowsher RR. The development, optimization and validation of an ELISA bioanalytical method for the determination of cetuximab in human serum. Anal Methods 2009; 1: 144-148.
35. Tran L, Beijnen JH, Huitema AD. The preparation of radiolabeled monoclonal antibodies for human use. Hum Antibodies 2009; 18: 145-156.
36. Liu G, Hnatowich DJ. Labeling biomolecules with radiorhenium: A review of the bifunctional chelators. Anticancer Agents Med Chem 2007; 7: 367-377.
37. Sakahara H, Endo K, Nakashima T, Koizumi M, Ohta H, Torizuka K, Furukawa T, Ohmomo Y, Yokoyama A, Okada K, et al. Effect of DTPA conjugation on the antigen binding activity and biodistribution of monoclonal antibodies against alpha-fetoprotein. J Nucl Med 1985; 26: 750-755.
38. Camera L, Kinuya S, Garmestani K, Wu CC, Brechbiel MW, Pai LH, Mcmurry TJ, Gansow OA, Pastan I, Paik CH, et al. Evaluation of the serum stability and in-vivo biodistribution of CHX-DTPA and other ligands for Yttrium labeling of monoclonal-antibodies. J Nucl Med 1994; 35: 882-889.
39. Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, Carrasquillo JA, Pastan I, Brechbiel MW. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem 1997; 5: 1925-1934.
40. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 111-129.
41. Blend MJ, Stastny JJ, Swanson SM, Brechbiel MW. Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent. Cancer Biother Radiopharm 2003; 18: 355-363.
42. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW. Cetuximab: Preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 2008; 23: 619-631.
43. Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab. Eur J Nucl Med Mol Imaging 2010; 37: 1368-1376.
44. Walrand S, Flux GD, Konijnenberg MW, Valkema R, Krenning EP, Lhommel R, Pauwels S, Jamar F. Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging? Eur J Nucl Med Mol Imaging 2011; 38: 57-68.